Details for Patent: 12,721,811
Which drugs does patent 12,721,811 protect, and when does it expire?
Patent 12,721,811 protects AXTLE and is included in one NDA.
Drugs Protected by US Patent 12,721,811
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avyxa Holdings | AXTLE | pemetrexed dipotassium | POWDER;INTRAVENOUS | 210661-001 | Jun 28, 2024 | RX | Yes | Yes | 12,721,811 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Avyxa Holdings | AXTLE | pemetrexed dipotassium | POWDER;INTRAVENOUS | 210661-002 | Jun 28, 2024 | RX | Yes | Yes | 12,721,811 | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
